Processa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewsWire · Sep 1, 2026
Processa Pharmaceuticals, Inc. (PCSA) M&A Call Prepared Remarks TranscriptSeeking Alpha · Jul 29, 2026
Processa buys Vidya Therapeutics, raises $200 million for drug trialsReuters · Jul 29, 2026
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC.GlobeNewsWire · Jul 29, 2026Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$1.00 | -$1.19 | Miss |
| May 7, 2026 | -$1.00 | -$1.29 | Miss |
| Mar 19, 2026 | -$1.50 | -$18.50 | Miss |
| Nov 6, 2025 | -$2.00 | -$1.75 | Beat |
| Aug 7, 2025 | -$5.75 | -$6.25 | Miss |
| May 8, 2025 | -$19.25 | -$7.50 | Beat |